Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of EryDex System in ataxia-telangiectasia
MOH_2017-04-24_000335Phase 3Not yet recruiting
- Sponsor
- EryDel S.p.A.
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone in ataxia-telangiectasia (AT) (3 arms), sponsored by EryDel S.p.A. Primary endpoint: Primary endpoint not specified. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on MOH_2017-04-24_000335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-24_000335.